Bionano Genomics, Inc. (BNGO) Social Stream



Bionano Genomics, Inc. (BNGO): $7.15

-0.10 (-1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNGO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

Featured Post From StockTwits About BNGO

$BNGO Look,BNGO will be a great company.Management is getting everything in place.They have a fantastic team and have been building out the workforce globally.This IS NOT a company with a share price to be monitored daily.Check it every Friday afternoon and Monday morning otherwise you’ll go nuts these days.Son’t waste your time with the Youtubers although Auspicious Dissent is a very good source of info.but you can waste a lot of time with speculative blather.Mr.Investalot is very good too with more concise videos while Dayo stumbles over his words and takes credit for all good news.The Weill-Cornell deal will be amazing!How Will it affect BNGO?Will it translate into more Saphyr being sold?It certainly will bring attention to Bionano and the company needs that.Long and strong and HODL.
CristoferAtlantis, published June 19, 2021

Other Notable StockTweets About BNGO


$BNGO Not aware of anyone freaking out. All I know is that the market goes up and down so does BNGO. It will have its day(s) and people will gloat and then it will have a red day and the shorts will gloat. Like everyone on this board says know what you own. I do, I am holding, I am ok??? with the slow movement upwards , we are not in the 5's people that was not long ago, we will be back in the teens not long from now, as long as you know what you own, PERIOD!!!!!!!

BrownVan, published June 15, 2021

$BNGO Brief summary of some BNGO features:
+Only viable alternative to outmoded, inefficient and messy current cytogenetic tools.
+Only tool capable of detecting large disease causing structural variants without error and without need for repeat tests.
+Very cost effective with little labor required.
+Highly praised by prestigious leaders in genomics and leading genomics institutions.
+$300 million+ in cash.
+Key executives the best, most accomplished, and most productive in the industry.
+Current cytogenetics field is $3 billion+ but BNGO is beginning to and will continue to expand that addressable market.
+Leading stock analysts have 9 month price target of $12-$15.
+Intellectual property portfolio includes digital sequencer that could make BNGO a one stop shop.
+Work is progressing (with some results already) to get insurance reimbursement codes for Saphyr.
+World wide adoptions for human as well as plant and non-human animal use.

Landsman, published June 11, 2021

$BNGO Love this slow grind action. Been in since Aug. 2020, not going anywhere. If this stock out lives me, I will will all my shares to my kids!

TheLittleGuyfromChicago, published June 4, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5066 seconds.